{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:32:22Z","timestamp":1792481542555,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd001747.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000}}],"reference-count":165,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001747.pub4","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T06:37:38Z","timestamp":1730788658000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment"],"prefix":"10.1002","volume":"2024","author":[{"given":"Amanda Wei Yin","family":"Lim","sequence":"additional","affiliation":[{"name":"Centre for Clinical Epidemiology; Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia; Shah Alam Malaysia"},{"name":"Statistical Genetics; QIMR Berghofer Medical Research Institute; Brisbane Australia"},{"name":"Faculty of Medicine; The University of Queensland; Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lon","family":"Schneider","sequence":"additional","affiliation":[{"name":"Keck School of Medicine; University of Southern California; Los Angeles CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement","family":"Loy","sequence":"additional","affiliation":[{"name":"Macquarie Medical School; Macquarie University; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD001747.pub4-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.euroneuro.2015.12.006","article-title":"Functional connectivity increase in the default-mode network of patients with Alzheimer's disease after long-term treatment with galantamine","volume":"26","author":"Blautzik","year":"2016","journal-title":"European Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD001747.pub4-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00406-011-0234-2","article-title":"Longitudinal changes of fractional anisotropy in Alzheimer's disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study","volume":"262","author":"Likitjaroen","year":"2012","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0003|cit3","unstructured":"Diffusion tensor weighted MRI in Alzheimer's disease modifying treatment effects of galantamine (Reminyl \u00ae ) clinicaltrials.gov\/ct2\/show\/NCT00523666"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD001747.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1016\/S0197-4580(96)80580-X","article-title":"Galanthamine hydrobromide: interim results of a group comparative, placebo-controlled, study of efficacy and safety in patients with a diagnosis of senile dementia of the Alzheimer's type","volume":"17","author":"Wilcock","year":"1996","journal-title":"Neurobiology of Aging"},{"issue":"9","key":"10.1002\/14651858.CD001747.pub4-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1002\/gps.409","article-title":"Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease","volume":"16","author":"Wilkinson","year":"2001","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0006|cit6","unstructured":"Kristensen M Richardson A Van Osselaer N Vangeneugden T Morrison S Fleet D A European multicentre placebo-controlled trial to determine the safety and efficacy of galantamine hydrobromide 40 mg\/day (32 mg\/day GAL base, tid dose regimen) in patients diagnosed with Alzheimer-type dementia Janssen Research Foundation Clinical Research Report Trial GAL-95-05"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0007|cit7","unstructured":"A randomized, double-blind, placebo-controlled trial of long-term (2-year) treatment of galantamine in mild to moderately-severe Alzheimer's disease clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2007-002780-27"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.2147\/NDT.S71540","article-title":"Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease [Corrigendum]","volume":"10","author":"Hager","year":"2014","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.2147\/NDT.S71540","article-title":"Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease [Corrigendum]","volume":"10","author":"Hager","year":"2014","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2147\/NDT.S57909","article-title":"Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease","volume":"10","author":"Hager","year":"2014","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0011|cit11","unstructured":"A study of galantamine used to treat patients with mild to moderate Alzheimer's disease clinicaltrials.gov\/ct2\/show\/NCT00679627"},{"issue":"1","key":"10.1002\/14651858.CD001747.pub4-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1474-4422(08)70261-8","article-title":"Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD) study: a randomised, placebo-controlled, double-blind trial","volume":"8","author":"Burns","year":"2009","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0013|cit13","unstructured":"Burns A Treatment of severe Alzheimer's disease in a residential home, nursing home, or geriatric residence setting: evaluation of efficacy and safety of galantamine (Reminyl \u00ae ) in a randomised, double-blind, placebo-controlled study yoda.yale.edu\/sites\/default\/files\/nct00216593.pdf 2008"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0014|cit14","unstructured":"Treatment of severe Alzheimer's disease: evaluation of efficacy and safety of galantamine hydrobromide in a controlled study clinicaltrials.gov\/ct2\/show\/record\/NCT00216593"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0015|cit15","unstructured":"Placebo-controlled evaluation of galantamine in the treatment of Alzheimer's disease: safety and efficacy of a controlled-release formulation Johnson & Johnson Pharmaceutical Research & Development, L.L.C"},{"issue":"2-3","key":"10.1002\/14651858.CD001747.pub4-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1159\/000086613","article-title":"Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease","volume":"20","author":"Brodaty","year":"2005","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0017|cit17","unstructured":"Placebo-controlled evaluation of galantamine in the treatment of Alzheimer's disease: safety and efficacy of a controlled-release formulation clinicaltrials.gov\/ct2\/show\/record\/NCT00253214"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0018|cit18","unstructured":"A randomized double-blind, placebo-controlled trial to evaluate the efficacy and safety of galantamine in subjects with mild cognitive impairment (MCI) clinically at risk for development of clinically probable Alzheimer\u2019s disease yoda.yale.edu\/sites\/default\/files\/nct00236574.pdf 2004"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0019|cit19","unstructured":"A study to evaluate the efficacy and safety of galantamine in patients with mild cognitive impairment clinicaltrials.gov\/ct2\/show\/NCT00236431"},{"issue":"22","key":"10.1002\/14651858.CD001747.pub4-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1212\/01.wnl.0000303815.69777.26","article-title":"Safety and efficacy of galantamine in subjects with mild cognitive impairment","volume":"70","author":"Winblad","year":"2008","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0021|cit21","unstructured":"A study to evaluate the efficacy and safety of galantamine in patients with mild cognitive impairment clinicaltrials.gov\/ct2\/show\/NCT00236431"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0022|cit22","unstructured":"A randomized double-blind, placebo-controlled trial to evaluate the efficacy and safety of galantamine in subjects with mild cognitive impairment (MCI) clinically at risk for development of clinically probable Alzheimer\u2019s disease yoda.yale.edu\/sites\/default\/files\/nct00236431.pdf 2004"},{"issue":"22","key":"10.1002\/14651858.CD001747.pub4-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1212\/01.wnl.0000303815.69777.26","article-title":"Safety and efficacy of galantamine in subjects with mild cognitive impairment","volume":"70","author":"Winblad","year":"2008","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0024|cit24","unstructured":"Long-term safety and efficacy of galantamine in the treatment of Alzheimer\u2019s disease yoda.yale.edu\/sites\/default\/files\/gal-int-3.pdf"},{"issue":"7274","key":"10.1002\/14651858.CD001747.pub4-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1136\/bmj.321.7274.1445","article-title":"Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial","volume":"321","author":"Wilcock","year":"2000","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0026|cit26","doi-asserted-by":"crossref","unstructured":"Wilcock GK Lilienfeld S Galantamine alleviates caregiver burden in Alzheimer's disease: a 6-month placebo-controlled study Conference Proceedings World Alzheimer Congress; 9-13 July, 2000, Washington 2000","DOI":"10.1016\/S0197-4580(00)83423-5"},{"issue":"7283","key":"10.1002\/14651858.CD001747.pub4-BIB0027|cit27","first-page":"405","article-title":"Erratum: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial","volume":"322","author":"Wilcock","year":"2001","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0028|cit28","unstructured":"A study of the safety and effectiveness of a flexible dose of galantamine versus placebo in the treatment of patients with Alzheimer's disease clinicaltrials.gov\/ct2\/show\/NCT00253227"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0029|cit29","unstructured":"Long-term safety and efficacy of galantamine in the treatment of Alzheimer\u2019s disease clinicaltrials.gov\/ct2\/show\/NCT00304629"},{"issue":"2","key":"10.1002\/14651858.CD001747.pub4-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/gps.1864","article-title":"Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months","volume":"23","author":"Rockwood","year":"2008","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD001747.pub4-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1136\/jnnp.71.5.589","article-title":"Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial","volume":"71","author":"Rockwood","year":"2001","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0032|cit32","unstructured":"IPD data package for study 'galantamine in the treatment of Alzheimer's disease: flexible dose range trial' and research request: 'meta-analysis of efficacy of cholinesterase inhibitors on individual neuropsychiatric symptoms in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies' https:\/\/vivli.org\/meta-analysis-of-efficacy-of-cholinesterase-inhibitors-on-individual-neuropsychiatric-symptoms-in-alzheimers-disease-parkinsons-disease-and-dementia-with-lewy-bodies\/ 10.25934\/00004683"},{"issue":"1-2","key":"10.1002\/14651858.CD001747.pub4-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000074140","article-title":"Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine","volume":"17","author":"Bullock","year":"2004","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"issue":"7","key":"10.1002\/14651858.CD001747.pub4-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1177\/0269881107083028","article-title":"Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6)","volume":"22","author":"Erkinjuntti","year":"2008","journal-title":"Journal of Psychopharmacology"},{"issue":"9314","key":"10.1002\/14651858.CD001747.pub4-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial","volume":"359","author":"Erkinjuntti","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0036|cit36","unstructured":"Erkinjuntti T Kurz A Gauthier S Bullock R Lilienfeld S Damaraju CV The safety and efficacy of galantamine in the treatment of vascular and mixed dementia (double-blind part only) yoda.yale.edu\/sites\/default\/files\/nct00261573.pdf 2004"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0022-510X(02)00267-8","article-title":"Treatment options: the latest evidence with galantamine (Reminyl\u00ae)","volume":"203-204","author":"Erkinjuntti","year":"2002","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/j.1749-6632.2002.tb04855.x","article-title":"Broad therapeutic benefits in patients with probable vascular dementia or Alzheimer's disease with cerebrovascular disease treated with galantamine","volume":"977","author":"Lilienfeld","year":"2002","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0039|cit39","unstructured":"A study on the safety and effectiveness of galantamine versus placebo in the treatment of patients with vascular dementia of mixed dementia clinicaltrials.gov\/ct2\/show\/NCT00261573"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0040|cit40","unstructured":"Hatakeyama Y and 90 other investigators Placebo-controlled confirmation study of galantamine (R113675) for Alzheimer type dementia ichgcp.net\/clinical-trials-registry\/NCT00814801 2009"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0041|cit41","unstructured":"An efficacy and safety study of galantamine for the treatment of patients with Alzheimer's disease clinicaltrials.gov\/ct2\/show\/NCT00814801"},{"issue":"5","key":"10.1002\/14651858.CD001747.pub4-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1176\/appi.ajgp.12.5.473","article-title":"Long-term outcomes of galantamine treatment in patients with Alzheimer disease","volume":"12","author":"Lyketsos","year":"2004","journal-title":"American Journal of Geriatric Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD001747.pub4-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","article-title":"A 5-month, randomized, placebo-controlled trial of galamtine in AD","volume":"54","author":"Tariot","year":"2000","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD001747.pub4-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1001\/archneur.61.2.252","article-title":"The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial","volume":"61","author":"Raskind","year":"2004","journal-title":"Archives of Neurology"},{"issue":"12","key":"10.1002\/14651858.CD001747.pub4-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","article-title":"Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension","volume":"54","author":"Raskind","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0046|cit46","unstructured":"Yoshida T and 70 other investigators (not named in study publication) Placebo-controlled double-blind comparative study of galantamine (R113675) in treatment of Alzheimer's disease filehosting.pharmacm.com\/DownloadService.ashx?client=CTR_JNJ_6051&studyid=403&filename=CR003301_CSR.pdf"},{"issue":"2","key":"10.1002\/14651858.CD001747.pub4-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.neurobiolaging.2006.09.020","article-title":"Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine","volume":"29","author":"Darreh-Shori","year":"2008","journal-title":"Neurobiology of Aging"},{"issue":"8","key":"10.1002\/14651858.CD001747.pub4-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.neurobiolaging.2007.02.020","article-title":"PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD","volume":"29","author":"Kadir","year":"2008","journal-title":"Neurobiology of Aging"},{"issue":"11","key":"10.1002\/14651858.CD001747.pub4-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3233\/JAD-2010-101290","article-title":"Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients","volume":"24","author":"Keller","year":"2011","journal-title":"Journal of Alzheimer's Disease"},{"issue":"3S","key":"10.1002\/14651858.CD001747.pub4-BIB0050|cit50","first-page":"130S","article-title":"Galantamine, a selective non-toxic acetylcholinesterase inhibitor is significantly superior over placebo in treatment of SDAT","volume":"10","author":"Kewitz","year":"1994","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD001747.pub4-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/153331750502000502","article-title":"Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study","volume":"20","author":"Koontz","year":"2005","journal-title":"American Journal of Alzheimer\u2019s Disease and Other Dementias"},{"issue":"1","key":"10.1002\/14651858.CD001747.pub4-BIB0052|cit52","first-page":"29","article-title":"Evaluation of galantamine in treatment of Alzheimer's disease: a multicentre, randomized, double-blind study","volume":"22","author":"Liu","year":"2003","journal-title":"[Chinese Journal of New Drugs and Clinical Remedies]"},{"issue":"9","key":"10.1002\/14651858.CD001747.pub4-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/jnnp.2008.166801","article-title":"Misplacing objects in mild to moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial","volume":"80","author":"Hamilton","year":"2009","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0054|cit54","unstructured":"The Video Imaging Synthesis of Treating Alzheimer's disease study isrctn.com\/ISRCTN26167328"},{"issue":"2","key":"10.1002\/14651858.CD001747.pub4-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/gps.2319","article-title":"The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease","volume":"25","author":"Rockwood","year":"2010","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD001747.pub4-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1503\/cmaj.051432","article-title":"Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial","volume":"174","author":"Rockwood","year":"2006","journal-title":"CMAJ"},{"issue":"10","key":"10.1002\/14651858.CD001747.pub4-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.jalz.2017.02.005","article-title":"Clinical meaningfulness of Alzheimer's Disease Assessment Scale-Cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors","volume":"13","author":"Rockwood","year":"2017","journal-title":"Alzheimer's & Dementia"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0058|cit58","unstructured":"Rockwood K Stanley J Howlett SE Differences in treatment response between males and females with mild-moderate Alzheimer disease being treated with cholinesterase inhibitors Journal of Prevention of Alzheimer's Disease 2018 S62 10.14283\/jpad.2018.40"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0059|cit59","doi-asserted-by":"crossref","unstructured":"Rockwood MRH Schindler R Howlett SE Rockwood K Increasing frailty was associated with a greater chance of notattaining goals in the VISTA clinical trial of galantamine Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2016 P826 (P3 023) 10.1016\/j.jalz.2016.06.1680","DOI":"10.1016\/j.jalz.2016.06.1680"},{"issue":"4","key":"10.1002\/14651858.CD001747.pub4-BIB0060|cit60","first-page":"223","article-title":"Galantamine in treating age-associated memory impairment and Alzheimer's disease by double blind method","volume":"9","author":"Xie","year":"2003","journal-title":"[Geriatric Health Care]"},{"issue":"3","key":"10.1002\/14651858.CD001747.pub4-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2165\/00002512-200926030-00004","article-title":"Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post hoc analysis of a randomized, double-blind, placebo-controlled trial","volume":"26","author":"Aronson","year":"2009","journal-title":"Drugs & Aging"},{"issue":"7","key":"10.1002\/14651858.CD001747.pub4-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"P901 (P4","DOI":"10.1016\/j.jalz.2015.08.133","article-title":"A randomized trial of the adherence and tolerability of acetylcholinesterase inhibitors","volume":"11","author":"Campbell","year":"2015","journal-title":"Alzheimer\u2019s & Dementia: The Journal of the Alzheimer\u2019s Association"},{"issue":"7","key":"10.1002\/14651858.CD001747.pub4-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/jgs.14827","article-title":"Adherence and tolerability of Alzheimer's disease medications: a pragmatic randomized trial","volume":"65","author":"Campbell","year":"2017","journal-title":"Journal of the American Geriatrics Society"},{"issue":"6","key":"10.1002\/14651858.CD001747.pub4-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1590\/0004-282X20140055","article-title":"Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study)","volume":"72","author":"Caramelli","year":"2014","journal-title":"Arquivos de Neuro-Psiquiatria"},{"issue":"5","key":"10.1002\/14651858.CD001747.pub4-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1017\/S1041610208007230","article-title":"Decreased initiation of usual activities in people with mild-to-moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial","volume":"20","author":"Cook","year":"2008","journal-title":"International Psychogeriatrics"},{"issue":"2","key":"10.1002\/14651858.CD001747.pub4-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/WAD.0b013e318193cbef","article-title":"Verbal repetition in people with mild-to-moderate Alzheimer disease: a descriptive analysis from the VISTA clinical trial","volume":"23","author":"Cook","year":"2009","journal-title":"Alzheimer Disease and Associated Disorders"},{"issue":"3","key":"10.1002\/14651858.CD001747.pub4-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.clinthera.2006.03.002","article-title":"Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month study","volume":"28","author":"Dunbar","year":"2006","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD001747.pub4-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1600-0404.2011.01594.x","article-title":"Two galantamine titration regimens in patients switched from donepezil","volume":"126","author":"Engedal","year":"2012","journal-title":"Acta Neurologica Scandinavica"},{"issue":"3-4","key":"10.1002\/14651858.CD001747.pub4-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1159\/000362204","article-title":"Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study","volume":"38","author":"Freund-Levi","year":"2014","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"issue":"3","key":"10.1002\/14651858.CD001747.pub4-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.3233\/JAD-201501","article-title":"Interventional study to evaluate the clinical effects and safety of the nutraceutical compound BrainUp-10\u00ae in a cohort of patients with Alzheimer's disease: a multicenter, randomized, double-blind, and placebo-controlled trial","volume":"81","author":"Guzman-Martinez","year":"2021","journal-title":"Journal of Alzheimer's Disease"},{"issue":"1","key":"10.1002\/14651858.CD001747.pub4-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13195-016-0214-x","article-title":"Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer's disease: post-hoc analysis of a randomized placebo-controlled study. Additional file 8","volume":"8","author":"Hager","year":"2016","journal-title":"Alzheimer's Research & Therapy"},{"issue":"1","key":"10.1002\/14651858.CD001747.pub4-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13195-016-0214-x","article-title":"Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer's disease: post-hoc analysis of a randomized placebo-controlled study","volume":"8","author":"Hager","year":"2016","journal-title":"Alzheimer's Research & Therapy"},{"issue":"4","key":"10.1002\/14651858.CD001747.pub4-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.3233\/JAD-210011","article-title":"Safety and tolerability of GRF6019 infusions in severe Alzheimer's disease: a phase II double-blind placebo-controlled trial","volume":"81","author":"Hannestad","year":"2021","journal-title":"Journal of Alzheimer's Disease"},{"issue":"9","key":"10.1002\/14651858.CD001747.pub4-BIB0074|cit74","first-page":"S1","article-title":"Galantamine-ER for cognitive deficits in bipolar disorder","volume":"79","author":"Iosifescu","year":"2016","journal-title":"Biological Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD001747.pub4-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s11055-008-9077-3","article-title":"Efficacy and safety of galantamine (Reminyl) for dementia in patients with Parkinson's disease (an open controlled trial)","volume":"38","author":"Litvinenko","year":"2008","journal-title":"Neuroscience and Behavioral Physiology"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0076|cit76","unstructured":"A cardiac safety of galantamine in the treatment of Alzheimer's disease clinicaltrials.gov\/ct2\/show\/NCT00309725"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0077|cit77","unstructured":"Study of the safety and effectiveness of two doses of investigational study drug EVP-6124 in subjects with Alzheimer's disease clinicaltrials.gov\/ct2\/show\/NCT01969136"},{"issue":"1","key":"10.1002\/14651858.CD001747.pub4-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/156720509787313961","article-title":"Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients","volume":"6","author":"Nordberg","year":"2009","journal-title":"Current Alzheimer Research"},{"issue":"2","key":"10.1002\/14651858.CD001747.pub4-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2174\/15672050113106660167","article-title":"The prediction of response to galantamine treatment in patients with mild to moderate Alzheimer's disease","volume":"11","author":"Ohnishi","year":"2014","journal-title":"Current Alzheimer Research"},{"issue":"11","key":"10.1002\/14651858.CD001747.pub4-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1185\/030079904X12555","article-title":"Effects of galantamine in patients with mild Alzheimer's disease","volume":"20","author":"Orgogozo","year":"2004","journal-title":"Current Medical Research and Opinion"},{"issue":"2","key":"10.1002\/14651858.CD001747.pub4-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/j.1600-0404.2010.01435.x","article-title":"Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease","volume":"124","author":"Parnetti","year":"2011","journal-title":"Acta Neurologica Scandinavica"},{"issue":"6","key":"10.1002\/14651858.CD001747.pub4-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s12603-012-0062-8","article-title":"A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI","volume":"16","author":"Peters","year":"2012","journal-title":"Journal of Nutrition, Health & Aging"},{"issue":"3","key":"10.1002\/14651858.CD001747.pub4-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.trci.2015.10.001","article-title":"Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug na\u00efve patients with mild-to-moderate Alzheimer's disease","volume":"1","author":"Peters","year":"2015","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"11","key":"10.1002\/14651858.CD001747.pub4-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/j.1468-1331.2004.00885.x","article-title":"Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial","volume":"11","author":"Pirttil\u00e4","year":"2004","journal-title":"European Journal of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD001747.pub4-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/alzrt275","article-title":"The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial","volume":"6","author":"Prins","year":"2014","journal-title":"Alzheimer's Research & Therapy"},{"issue":"4","key":"10.1002\/14651858.CD001747.pub4-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"S800 (P4","DOI":"10.1016\/j.jalz.2011.05.2305","article-title":"Efficacy and tolerability of two galantamine titration regimens in patients switched from donepezil","volume":"7","author":"Richarz","year":"2011","journal-title":"Alzheimer's & Dementia: The Journal of the Alzheimer's Association"},{"issue":"2","key":"10.1002\/14651858.CD001747.pub4-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/gps.1864","article-title":"Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months","volume":"23","author":"Rockwood","year":"2008","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001747.pub4-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/ana.25775","article-title":"Nilotinib effects on safety, tolerability, and biomarkers in Alzheimer's disease","volume":"88","author":"Turner","year":"2020","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD001747.pub4-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2174\/156720511795256053","article-title":"EHT0202 in Alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study","volume":"8","author":"Vellas","year":"2011","journal-title":"Current Alzheimer Research"},{"issue":"3","key":"10.1002\/14651858.CD001747.pub4-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/arclin\/acy032","article-title":"Attention measures of accuracy, variability, and fatigue detect early response to donepezil in Alzheimer's disease: a randomized, double-blind, placebo-controlled pilot trial","volume":"34","author":"Vila-Castelar","year":"2019","journal-title":"Archives of Clinical Neuropsychology"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.trci.2018.03.004","article-title":"Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease","volume":"4","author":"Voss","year":"2018","journal-title":"Alzheimer's and Dementia: Translational Research and Clinical Interventions"},{"issue":"3","key":"10.1002\/14651858.CD001747.pub4-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/BF03096196","article-title":"Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands","volume":"41","author":"Wouters","year":"2010","journal-title":"Tijdschrift voor Gerontologie en Geriatrie"},{"issue":"3","key":"10.1002\/14651858.CD001747.pub4-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"233","DOI":"10.30773\/pi.2020.0329","article-title":"The behavioral effects of combination therapy of memantine and acetylcholinesterase inhibitors compared with acetylcholinesterase inhibitors alone in patients with moderate Alzheimer's dementia: a double-blind randomized placebo-controlled trial","volume":"18","author":"Youn","year":"2021","journal-title":"Psychiatry Investigation"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2147\/NDT.S38747","article-title":"Galantamine versus donepezil in Chinese patients with Alzheimer's disease: results from a randomized, double-blind study","volume":"8","author":"Zhang","year":"2012","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/00002093-200108001-00004","article-title":"Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease","volume":"15 Suppl 1","author":"Albuquerque","year":"2001","journal-title":"Alzheimer Disease and Associated Disorders"},{"issue":"3","key":"10.1002\/14651858.CD001747.pub4-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/alz.12328","article-title":"2021 Alzheimer's disease facts and figures","volume":"17","author":"Alzheimer's Association","year":"2021","journal-title":"Alzheimer's & Dementia"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.trci.2019.06.005","article-title":"Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials","volume":"5","author":"Andrews","year":"2019","journal-title":"Alzheimer's & Dementia"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0098|cit98","volume-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM IIIR","author":"American Psychiatric Association (APA)","year":"1987"},{"issue":"4","key":"10.1002\/14651858.CD001747.pub4-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD001747.pub4-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"CD013306","DOI":"10.1002\/14651858.CD013306.pub2","article-title":"Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis","volume":"2","author":"Battle","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD001747.pub4-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"192","DOI":"10.2165\/00003088-199529030-00005","article-title":"Geographical\/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19","volume":"29","author":"Bertilsson","year":"1995","journal-title":"Clinical Pharmacokinetics"},{"issue":"1-2","key":"10.1002\/14651858.CD001747.pub4-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000074140","article-title":"Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine","volume":"17","author":"Bullock","year":"2004","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"issue":"12","key":"10.1002\/14651858.CD001747.pub4-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD001747.pub4-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3233\/JAD-180766","article-title":"Treatment combinations for Alzheimer's Disease: current and future pharmacotherapy options","volume":"67","author":"Cummings","year":"2019","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0105|cit105","unstructured":"Deeks JJ Higgins JP Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD001747.pub4-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3233\/JAD-122140","article-title":"A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease","volume":"35","author":"Di Santo","year":"2013","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"956354","DOI":"10.1155\/2012\/956354","article-title":"Trends in the prevalence of dementia in Japan","volume":"2012","author":"Dodge","year":"2012","journal-title":"International Journal of Alzheimer's Disease"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0108|cit108","volume-title":"Treatment of Early Breast Cancer: Worldwide Evidence, 1985-1990","author":"Early Breast Cancer Trialists' Collaborative Group","year":"1990"},{"issue":"7109","key":"10.1002\/14651858.CD001747.pub4-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0110|cit110","unstructured":"Peripheral and Central Nervous System Drugs Advisory Committee Meeting, July 7, 1989 Rockville, MD: Department of Health and Human Services, Public Health Service"},{"issue":"3","key":"10.1002\/14651858.CD001747.pub4-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\"Mini-mental state\". A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study","volume":"11 Suppl 2","author":"Galasko","year":"1997","journal-title":"Alzheimer Disease and Associated Disorders"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0113|cit113","unstructured":"Gauthier S Rosa-Neto P Morais JA Webster C World Alzheimer Report 2021: Journey Through the Diagnosis of Dementia www.alzint.org\/u\/World-Alzheimer-Report-2021.pdf"},{"issue":"5","key":"10.1002\/14651858.CD001747.pub4-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"471","DOI":"10.5014\/ajot.53.5.471","article-title":"Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia","volume":"53","author":"G\u00e9linas","year":"1999","journal-title":"American Journal of Occupational Therapy"},{"issue":"7650","key":"10.1002\/14651858.CD001747.pub4-BIB0115|cit115","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD001747.pub4-BIB0116|cit116","first-page":"211","article-title":"Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis","volume":"3","author":"Hansen","year":"2008","journal-title":"Clinical Interventions in Aging"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0117|cit117","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0118|cit118","unstructured":"Higgins JP Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0119|cit119","unstructured":"Higgins JP Li T Chapter 6: Choosing effect measures and computing estimates of effect [last updated August 2023]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from www.training.cochrane.org\/handbook"},{"issue":"8","key":"10.1002\/14651858.CD001747.pub4-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/gps.2607","article-title":"Determining the minimum clinically important differences for outcomes in the DOMINO trial","volume":"26","author":"Howard","year":"2011","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"7512","key":"10.1002\/14651858.CD001747.pub4-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1136\/bmj.331.7512.321","article-title":"Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials","volume":"331","author":"Kaduszkiewicz","year":"2005","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD001747.pub4-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2174\/156720511795256044","article-title":"Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease","volume":"8","author":"Kavanagh","year":"2011","journal-title":"Current Alzheimer Research"},{"issue":"11","key":"10.1002\/14651858.CD001747.pub4-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3233\/JAD-2010-101290","article-title":"Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients","volume":"24","author":"Keller","year":"2011","journal-title":"Journal of Alzheimer's Disease"},{"issue":"1","key":"10.1002\/14651858.CD001747.pub4-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9758\/cpn.2017.15.1.1","article-title":"Mechanisms of Alzheimer\u2019s disease pathogenesis and prevention: the brain, neural pathology, N-methyl-D-aspartate receptors, tau protein and other risk factors","volume":"15","author":"Kocahan","year":"2017","journal-title":"Clinical Psychopharmacology and Neuroscience"},{"issue":"6","key":"10.1002\/14651858.CD001747.pub4-BIB0125|cit125","first-page":"557","article-title":"Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis","volume":"169","author":"Lanct\u00f4t","year":"2003","journal-title":"CMAJ"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"937486","DOI":"10.3389\/fnagi.2022.937486","article-title":"Global, regional, and national burden of Alzheimer's disease and other dementias, 1990\u20132019","volume":"14","author":"Li","year":"2022","journal-title":"Frontiers in Aging Neuroscience"},{"issue":"4","key":"10.1002\/14651858.CD001747.pub4-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00406-011-0234-2","article-title":"Longitudinal changes of fractional anisotropy in Alzheimer's disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study","volume":"262","author":"Likitjaroen","year":"2012","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"4","key":"10.1002\/14651858.CD001747.pub4-BIB0128|cit128","first-page":"427","article-title":"Pharmacokinetic and other related factors affecting psychotropic responses in Asians","volume":"27","author":"Lin","year":"1991","journal-title":"Psychopharmacology Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD001747.pub4-BIB0129|cit129","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1046\/j.1365-2125.1999.00026.x","article-title":"Acetylcholinesterase inhibitors in Alzheimer's disease","volume":"48","author":"McGleenon","year":"1999","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"7","key":"10.1002\/14651858.CD001747.pub4-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/00002093-199700112-00003","article-title":"Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study","volume":"11 Suppl 2","author":"Mohs","year":"1997","journal-title":"Alzheimer Disease and Associated Disorders"},{"issue":"2","key":"10.1002\/14651858.CD001747.pub4-BIB0132|cit132","first-page":"e31","article-title":"Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review","volume":"3","author":"Molnar","year":"2009","journal-title":"Open Medicine"},{"issue":"11","key":"10.1002\/14651858.CD001747.pub4-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/wnl.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD001747.pub4-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1002\/alz.13770","article-title":"Minimal clinically important difference in Alzheimer's disease: rapid review","volume":"20","author":"Muir","year":"2024","journal-title":"Alzheimer's & Dementia: The Journal of the Alzheimer's Association"},{"issue":"2","key":"10.1002\/14651858.CD001747.pub4-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0376-8716(02)00111-4","article-title":"Intention-to-treat meets missing data: implications of alternate strategies for analyzing clinical trials data","volume":"68","author":"Nich","year":"2002","journal-title":"Drug and Alcohol Dependence"},{"issue":"20","key":"10.1002\/14651858.CD001747.pub4-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1212\/WNL.0000000000003932","article-title":"Trends in dementia prevalence, incidence, and survival rate in a Japanese community","volume":"88","author":"Ohara","year":"2017","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0137|cit137","first-page":"CMT.S5884","article-title":"Efficacy and safety of galantamine hydrobromide in the treatment of mild to moderate dementia","volume":"2","author":"Oremus","year":"2010","journal-title":"Clinical Medicine Insights: Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD001747.pub4-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s12640-013-9398-z","article-title":"Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease","volume":"24","author":"Parsons","year":"2013","journal-title":"Neurotoxicity Research"},{"issue":"2","key":"10.1002\/14651858.CD001747.pub4-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"CD009081","DOI":"10.1002\/14651858.CD009081.pub2","article-title":"Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia","volume":"2","author":"Parsons","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD001747.pub4-BIB0140|cit140","doi-asserted-by":"publisher","first-page":"9809","DOI":"10.3390\/ijms15069809","article-title":"Inhibitors of acetylcholinesterase and butyrylcholinesterase meet immunity","volume":"15","author":"Pohanka","year":"2014","journal-title":"International Journal of Molecular Sciences"},{"issue":"8","key":"10.1002\/14651858.CD001747.pub4-BIB0141|cit141","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1111\/j.1742-1241.2008.01808.x","article-title":"The impact of analytic method on interpretation of outcomes in longitudinal clinical trials","volume":"62","author":"Prakash","year":"2008","journal-title":"International Journal of Clinical Practice"},{"issue":"4","key":"10.1002\/14651858.CD001747.pub4-BIB0142|cit142","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/j.1532-5415.1995.tb05823.x","article-title":"Prospective meta-analysis: ahoy! A clinical trial?","volume":"43","author":"Probstfield","year":"1995","journal-title":"Journal of the American Geriatrics Society"},{"issue":"4","key":"10.1002\/14651858.CD001747.pub4-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.bcp.2013.12.024","article-title":"Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers","volume":"88","author":"Reitz","year":"2014","journal-title":"Biochemical Pharmacology"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0144|cit144","unstructured":"Review Manager (RevMan) The Cochrane Collaboration, 2024 2024"},{"issue":"2","key":"10.1002\/14651858.CD001747.pub4-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/gps.2319","article-title":"The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease","volume":"25","author":"Rockwood","year":"2010","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD001747.pub4-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer's disease","volume":"141","author":"Rosen","year":"1984","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0147|cit147","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1007\/978-1-4612-4116-4_64","article-title":"Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study","volume":"11 Suppl 2","author":"Schneider","year":"1997","journal-title":"Alzheimer's Disease and Associated Disorders"},{"issue":"2","key":"10.1002\/14651858.CD001747.pub4-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1136\/jnnp-2011-300881","article-title":"What is the clinically relevant change on the ADAS-Cog?","volume":"83","author":"Schrag","year":"2012","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0149|cit149","unstructured":"Stata StataCorp 2013"},{"issue":"4","key":"10.1002\/14651858.CD001747.pub4-BIB0150|cit150","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/ageing\/afl027","article-title":"Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing!","volume":"35","author":"Tabet","year":"2006","journal-title":"Age and Ageing"},{"issue":"1","key":"10.1002\/14651858.CD001747.pub4-BIB0151|cit151","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/gps.1402","article-title":"A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease","volume":"21","author":"Takeda","year":"2006","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0152|cit152","unstructured":"Thomas J Askie LM Berlin JA Elliott JH Ghersi D Simmonds M Chapter 22: Prospective approaches to accumulating evidence [last updated October 2019]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from www.training.cochrane.org\/handbook"},{"issue":"9","key":"10.1002\/14651858.CD001747.pub4-BIB0153|cit153","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1345\/aph.1H658","article-title":"Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care","volume":"41","author":"Thomsen","year":"2007","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0154|cit154","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1745-6215-12-104","article-title":"The methodology for developing a prospective meta-analysis in the family planning community","volume":"12","author":"Turok","year":"2011","journal-title":"Trials"},{"issue":"1","key":"10.1002\/14651858.CD001747.pub4-BIB0155|cit155","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12874-021-01228-7","article-title":"Using a distribution-based approach and systematic review methods to derive minimum clinically important differences","volume":"21","author":"Watt","year":"2021","journal-title":"BMC Medical Research Methodology"},{"issue":"8","key":"10.1002\/14651858.CD001747.pub4-BIB0156|cit156","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/bjp.2008.185","article-title":"Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans","volume":"154","author":"Wessler","year":"2008","journal-title":"British Journal of Pharmacology"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0157|cit157","unstructured":"World Health Organization and Alzheimer's Disease International Dementia: a public health priority apps.who.int\/iris\/bitstream\/10665\/75263\/1\/9789241564458_eng.pdf?ua=1"},{"key":"10.1002\/14651858.CD001747.pub4-BIB0158|cit158","unstructured":"Mathers C Boerma T Ma Fat D The global burden of disease: 2004 update World Health Organization; 2008. www.who.int\/healthinfo\/global_burden_disease\/GBD_report_2004update_full.pdf"},{"issue":"7","key":"10.1002\/14651858.CD001747.pub4-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00002512-200421070-00004","article-title":"Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy","volume":"21","author":"Wilkinson","year":"2004","journal-title":"Drugs & Aging"},{"issue":"22","key":"10.1002\/14651858.CD001747.pub4-BIB0160|cit160","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1212\/01.wnl.0000303815.69777.26","article-title":"Safety and efficacy of galantamine in subjects with mild cognitive impairment","volume":"70","author":"Winblad","year":"2008","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD001747.pub4-BIB0161|cit161","first-page":"7423","article-title":"Efficacy of galantamine in treatment of Alzheimer's disease: an update meta-analysis","volume":"9","author":"Zhang","year":"2016","journal-title":"International Journal of Clinical and Experimental Medicine"},{"issue":"3","key":"10.1002\/14651858.CD001747.pub4-BIB0162|cit162","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2174\/1570159X11311030006","article-title":"Acetylcholinesterase inhibitors: pharmacology and toxicology","volume":"11","author":"Colovi\u0107","year":"2013","journal-title":"Current Neuropharmacology"},{"issue":"4","key":"10.1002\/14651858.CD001747.pub4-BIB0163|cit163","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001747.pub3","article-title":"Galantamine for Alzheimer's disease","author":"Loy","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD001747.pub4-BIB0164|cit164","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001747.pub3","article-title":"Galantamine for Alzheimer's disease and mild cognitive impairment","author":"Loy","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD001747.pub4-BIB0165|cit165","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001747","article-title":"Galantamine for Alzheimer's disease","author":"Olin","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T19:49:43Z","timestamp":1767815383000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001747.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":165,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001747.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,5]]}}}